Complete Tirzepatide Guide
Information about tirzepatide, the medication in the prescription brands Zepbound and Mounjaro, including dosing, side effects and questions to discuss with a licensed provider.
Brand-drug trial evidence
In SURMOUNT-1, participants receiving the highest studied dose of tirzepatide, 15 mg weekly, had a mean body-weight reduction of 20.9% at 72 weeks. This was a trial of the brand drug, not compounded tirzepatide; it does not establish an outcome for compounded tirzepatide.
Mechanism
Tirzepatide acts at GIP and GLP-1 receptors.
Once-Weekly Injection
Convenient dosing schedule that fits seamlessly into your routine
Comprehensive Resource Library
Explore our expertly curated guides covering every aspect of tirzepatide treatment.
Cost & Affordability
Complete breakdown of tirzepatide costs, insurance coverage options, and strategies for affordable access.
- Tirzepatide pricing guide
- Insurance coverage strategies
- Mounjaro vs Zepbound costs
- Savings programs availability
Getting Started
Everything you need to begin tirzepatide treatment, from eligibility to your first injection.
- Tirzepatide eligibility
- Starting tirzepatide guide
- First month expectations
- Provider selection tips
Dosage & Administration
Master tirzepatide dosing schedules, proper injection technique, and administration guidelines.
- Tirzepatide dosing schedule
- Dose escalation protocol
- Injection best practices
- Managing dose adjustments
Side Effects Management
Learn to identify, manage, and minimize side effects for optimal comfort during treatment.
- Common side effects
- Gastrointestinal management
- Dietary adjustments
- Safety monitoring
Results & Effectiveness
Understand realistic expectations, timelines, and strategies for maximizing weight loss results.
- Weight loss expectations
- Clinical trial results
- Long-term outcomes
- Success optimization
Comparisons
Compare tirzepatide with semaglutide and other treatments to make informed decisions.
- Tirzepatide vs Semaglutide
- Mounjaro vs Zepbound
- Dual-action benefits
- Effectiveness comparison
What is Tirzepatide?
Tirzepatide acts at GIP and GLP-1 receptors. Zepbound is a prescription brand used for weight management, and Mounjaro is a prescription brand used for type 2 diabetes. Compounded tirzepatide is not either brand and is not FDA-approved.
In SURMOUNT-1, participants receiving the highest studied dose of tirzepatide, 15 mg weekly, had a mean body-weight reduction of 20.9% at 72 weeks. This was a trial of the brand drug, not compounded tirzepatide; it does not establish an outcome for compounded tirzepatide.
Zepbound is FDA-approved, alongside a reduced-calorie diet and increased physical activity, to reduce excess weight and maintain weight reduction in adults with obesity, or adults with overweight and at least one weight-related condition. This approval applies to Zepbound, not compounded tirzepatide. A licensed provider decides whether a treatment is appropriate.
Ready to Start Your Tirzepatide Journey?
Discuss your medical history, treatment options and questions with a licensed provider.